These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35213655)

  • 1. Suvorexant and mirtazapine improve chronic pain-related changes in parameters of sleep and voluntary physical performance in mice with sciatic nerve ligation.
    Ito H; Tsuneki H; Sasaoka T; Toyooka N; Matsuo M; Yamazaki M
    PLoS One; 2022; 17(2):e0264386. PubMed ID: 35213655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
    Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mirtazapine on sleep disturbance under neuropathic pain-like state.
    Enomoto T; Yamashita A; Torigoe K; Horiuchi H; Hirayama S; Nakahara K; Yanase M; Sakai H; Ikegami D; Nagase H; Suzuki T; Iseki M; Inada E; Narita M
    Synapse; 2012 Jun; 66(6):483-8. PubMed ID: 22213404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the effects of a tricyclic antidepressant on secondary sleep disturbance induced by chronic pain in a preclinical model.
    Ito H; Takemura Y; Aoki Y; Hattori M; Horikawa H; Yamazaki M
    PLoS One; 2020; 15(12):e0243325. PubMed ID: 33270791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
    Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
    J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of orexin receptor antagonist and GABA
    Seol J; Fujii Y; Park I; Suzuki Y; Kawana F; Yajima K; Fukusumi S; Okura T; Satoh M; Tokuyama K; Kokubo T; Yanagisawa M
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24353-24358. PubMed ID: 31712421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
    Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
    Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
    Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
    Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant improves intractable nocturnal enuresis by altering sleep architecture.
    Matsumoto T
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33727289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.
    Aslan S; Isik E; Cosar B
    Sleep; 2002 Sep; 25(6):677-9. PubMed ID: 12224847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
    Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
    Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
    JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
    Shen J; Chung SA; Kayumov L; Moller H; Hossain N; Wang X; Deb P; Sun F; Huang X; Novak M; Appleton D; Shapiro CM
    Can J Psychiatry; 2006 Jan; 51(1):27-34. PubMed ID: 16491981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of sleep disorders under pain using an optogenetic tool: possible involvement of the activation of dorsal raphe nucleus-serotonergic neurons.
    Ito H; Yanase M; Yamashita A; Kitabatake C; Hamada A; Suhara Y; Narita M; Ikegami D; Sakai H; Yamazaki M; Narita M
    Mol Brain; 2013 Dec; 6():59. PubMed ID: 24370235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.